There were 2,349 press releases posted in the last 24 hours and 447,259 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image